Submit to Pharmaceutics Review for Pharmaceutics Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 10418

Share This Special Issue

Special Issue Editor

Prof. Dr. Sophia G. Antimisiaris

E-Mail Website1 Website2
Guest Editor

1. Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, 26510 Rio-Patras, Greece
2. Institute for Chemical Engineering Sciences, Foundation for Research and Technology Hellas, FORTH/ICE-HT, Stadiou Street, 26504 Platani-Rio, Greece
Interests: targeted drug delivery; nanomedicines; liposome technology; lipid-based formulations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

The therapeutic potential of certain categories of drugs, such as drugs with high molecular weight, low aqueous solubility, and/or high permeability, narrow therapeutic range and also drugs that are liable in blood and/or at the site of administration/absorption, cannot be manifested unless particular delivery challenges are overcome. The design and development of liposomal drugs may offer solutions to such delivery problems, especially if the liposomal carriers can reach, and deliver the associated drug to their specific biological targets. In addition to Drug Delivery solutions, liposomes can offer solutions to vaccination limitations. Vaccination is often hampered by the presence of infectious agents, weak immune responses and prohibiting costs, especially in the developing world. Such problems may be circumvented by immunisation with nucleic acids (eg. plasmid DNA, siRNA, mRNA), especially when associated with cationic lipids in the form of liposomes and other lipid-based nanoparticles, as exemplified by the current efforts for the prevention of Covid 19 virus pandemic. The contributors of the present volume deal with the background and progress made so far with liposomes for drug delivery and targeting, as well as vaccines, (especially nucleic acid vaccines). Theoretical and practical advantages as well as potential risks are discussed.

Keywords

liposomes for drug delivery (for therapy of cancer, infectious diseases, neurodegenerative diseases, etc.)
development, applications, and challenges of ligand-targeted liposomal drugs
liposomes and biological barriers
liposomes as immunological adjuvants
cationic liposomes and lipid nanoparticles as vaccine carriers
immunization with nucleic acids in liposomes
entrapment of nucleic acid vaccines in cationic liposomes

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Synthesis of Novel Arsonolipids and Development of Novel Arsonoliposome Types

Spyridon Mourtas

Konstantina Papadia

Golfo G. Kordopati

Panayiotis V. Ioannou

Sophia G. Antimisiaris

and

Gerasimos M. Tsivgoulis

Pharmaceutics 2022, 14(8), 1649; https://doi.org/10.3390/pharmaceutics14081649 - 08 Aug 2022

Cited by 1 | Viewed by 930

Abstract

Arsonolipids represent a class of arsenic-containing compounds with interesting biological properties either as monomers or as nanostructure forming components, such as arsonoliposomes that possess selective anticancer activity as proven by in vitro and in vivo studies. In this work, we describe, for the first time, the synthesis of novel arsono-containing lipids where the alkyl groups are connected through stable ether bonds. It is expected that this class of arsonolipids, compared with the corresponding ester linked, will have higher chemical stability. To accomplish this task, a new methodology of general application was developed, where a small arsono compound, 2-hydroxyethylarsonic acid, when protected with thiophenol, can be used in an efficient and simple way as a building block for the synthesis of arsono-containing lipids as well as other arsono-containing biomolecules. Thus, besides the above-mentioned arsonolipid, an arsono cholesterol derivative was also obtained. Both ether arsonolipid and arsono cholesterol were able to form liposomes having similar physicochemical properties and integrity to conventional arsonoliposomes. Furthermore, a preliminary in vitro anticancer potential assessment of the novel ether arsonolipid containing liposomes against human prostate cancer (PC-3) and Lewis lung carcinoma (LLC) cells showed significant activity (dose- and time-dependent), which was similar to that of the conventional arsonoliposomes (studied before). Given the fact that novel arsonolipids may be more stable compared to the ones used in conventional arsonoliposomes, the current results justify further exploitation of the novel compounds by in vitro and in vivo studies. Full article

(This article belongs to the Special Issue A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines)

► Show Figures

Graphical abstract

Open AccessArticle

“Endothelial Antibody Factory” at the Blood Brain Barrier: Novel Approach to Therapy of Neurodegenerative Diseases

and

Pharmaceutics 2022, 14(7), 1418; https://doi.org/10.3390/pharmaceutics14071418 - 06 Jul 2022

Cited by 1 | Viewed by 1673

Abstract

The failures of anti-β-amyloid immunotherapies suggested that the very low fraction of injected antibodies reaching the brain parenchyma due to the filtering effect of the BBB may be a reason for the lack of therapeutic effect. However, there is no treatment, as yet, for the amyotrophic lateral sclerosis (ALS) despite substantial evidence existing of the involvement of TDP-43 protein in the evolution of ALS. To circumvent this filtering effect, we have developed a novel approach to facilitate the penetration of antibody fragments (Fabs) into the brain parenchyma. Leveraging the homing properties of endothelial progenitor cells (EPCs), we transfected, ex vivo, such cells with vectors encoding anti-β-amyloid and anti-TDP43 Fabs turning them into an “antibody fragment factory”. When injected these cells integrate into the BBB, where they secrete anti-TDP43 Fabs. The results showed the formation of tight junctions between the injected engineered EPCs and the unlabeled resident endothelial cells. When the EPCs were further modified to express the anti-TDP43 Fab, we could observe integration of these cells into the vasculature and the secretion of Fabs. Results confirm that production and secretion of Fabs at the BBB level leads to their migration to the brain parenchyma where they might exert a therapeutic effect. Full article

(This article belongs to the Special Issue A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines)

► Show Figures

Figure 1

Open AccessArticle

The pH-Responsive Liposomes—The Effect of PEGylation on Release Kinetics and Cellular Uptake in Glioblastoma Cells

and

Pharmaceutics 2022, 14(6), 1125; https://doi.org/10.3390/pharmaceutics14061125 - 25 May 2022

Cited by 2 | Viewed by 1587

Abstract

Nanomedicine has been, to a certain degree, a success story in the development of superior anticancer therapies. However, there are tumors that remain a huge challenge for nanoformulations, for instance, brain tumors such as glioblastoma, the most common and aggressive brain tumor. To utilize the fact that such tumors are characterized by an acidic extracellular environment, we selected pH-responsive liposomes as a potential drug delivery system for superior delivery to GBM. Liposomes comprising PEGylated lipid of two chain lengths with encapsulated fluorescent marker calcein were characterized and challenged against non-PEGylated vesicles. The in vitro calcein release from three liposomal formulations (<200 nm), namely non-PEGylated (pH-Lip) and PEGylated, pH-Lip–PEG750, and pH-Lip–PEG2000, was followed at three pH conditions to prove the pH-responsiveness. The intracellular delivery of a liposomally encapsulated marker was determined in GL261 glioblastoma cell lines in vitro using both flow cytometry and confocal microscopy. The inclusion of PEG2000 within liposomal formulation resulted in reduced in vitro pH-responsiveness compared to pH-Lip and pH-Lip750. All three pH-responsive liposomal formulations improved intracellular uptake in GL261 cells compared to non-pH-responsive liposomes, with negligible differences regarding PEG length. The proposed formulations should be further evaluated in glioblastoma models. Full article

(This article belongs to the Special Issue A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines)

► Show Figures

Figure 1

Open AccessArticle

Inclusion of a Phytomedicinal Flavonoid in Biocompatible Surface-Modified Chylomicron Mimic Nanovesicles with Improved Oral Bioavailability and Virucidal Activity: Molecular Modeling and Pharmacodynamic Studies

and

Pharmaceutics 2022, 14(5), 905; https://doi.org/10.3390/pharmaceutics14050905 - 21 Apr 2022

Cited by 10 | Viewed by 1278

Abstract

Morin hydrate (MH) is a widely-used Asian phytomedicinal flavonoid with a wide range of reported therapeutic activities. However, MH has limited oral bioavailability due to its low aqueous solubility and intestinal permeability, which in turn hinders its potential antiviral activity. The study reported herein was designed to encapsulate MH in polyethyleneglycolated (PEGylated) chylomicrons (PCMs) and to boost its antiviral activity and biological availability for oral administration using a rat experimental model. The PEGylated edge activator combined with the conventional components of chylomicrons (CMs) amplify the transport of the drug across the intestine and its circulation period, hence its therapeutic impact. The implementation of variables in the in vitro characterization of the vesicles was investigated. Using Design Expert^® software, a 2⁴ factorial design was conducted, and the resulting PCM formulations were fabricated utilizing a thin-film hydration technique. The efficacy of the formulations was assessed according to their zeta potential (ZP), entrapment efficiency percentage (EE%), amount of drug released after 8 h (Q8h), and particle size (PS) data. Formulation F9, which was deemed to be the optimal formula, used compritol as the lipidic core together in defined amounts with phosphatidylcholine (PC) and Brij52. Computer-aided studies revealed that MH alone in a suspension had both diminished intestinal permeability and absorption, but was enhanced when loaded in PCMs. This was affirmed by the superiority of formulation F9 results in ex vivo permeation and pharmacokinetic studies. Furthermore, formulation F9 had a superior safety profile and antiviral activity over a pure MH suspension. Molecular-docking studies revealed the capability of MH to inhibit MERS-CoV 3CL^pro, the enzyme shown to exhibit a crucial role in viral replication. Additionally, F9 suppressed both MERS-CoV-induced histopathological alteration in lung tissue and resulting oxidative and inflammatory biomarkers. Collectively, the results reported herein affirmed the potential of PCMs as nanocarriers for the effective oral administration of MH as an antiviral. Full article

(This article belongs to the Special Issue A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines)

► Show Figures

Graphical abstract

Open AccessArticle

Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity against Staphylococcus epidermidis

and

Sophia G. Antimisiaris

Pharmaceutics 2022, 14(2), 370; https://doi.org/10.3390/pharmaceutics14020370 - 07 Feb 2022

Cited by 4 | Viewed by 1738

Abstract

The aim of this study was the development of optimal sustained-release moxifloxacin (MOX)-loaded liposomes as intraocular therapeutics of endophthalmitis. Two methods were compared for the preparation of MOX liposomes; the dehydration–rehydration (DRV) method and the active loading method (AL). Numerous lipid-membrane compositions were studied to determine the potential effect on MOX loading and retention in liposomes. MOX and phospholipid contents were measured by HPLC and a colorimetric assay for phospholipids, respectively. Vesicle size distribution and surface charge were measured by DLS, and morphology was evaluated by cryo-TEM. The AL method conferred liposomes with higher MOX encapsulation compared to the DRV method for all the lipid compositions used. Cryo-TEM showed that both liposome types had round vesicular structure and size around 100–150 nm, while a granular texture was evident in the entrapped aqueous compartments of most AL liposomes, but substantially less in DRV liposomes; X-ray diffraction analysis demonstrated slight crystallinity in AL liposomes, especially the ones with highest MOX encapsulation. AL liposomes retained MOX for significantly longer time periods compared to DRVs. Lipid composition did not affect MOX release from DRV liposomes but significantly altered drug loading/release in AL liposomes. Interestingly, AL liposomes demonstrated substantially higher antimicrobial potential towards S. epidermidis growth and biofilm susceptibility compared to corresponding DRV liposomes, indicating the importance of MOX retention in liposomes on their activity. In conclusion, the liposome preparation method/type determines the rate of MOX release from liposomes and modulates their antimicrobial potential, a finding that deserves further in vitro and in vivo exploitation. Full article

(This article belongs to the Special Issue A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Liposomes as Tools to Improve Therapeutic Enzyme Performance

Maria Eugénia Meirinhos Cruz

Maria Luísa Corvo

Maria Bárbara Martins

Sandra Simões

and

Maria Manuela Gaspar

Pharmaceutics 2022, 14(3), 531; https://doi.org/10.3390/pharmaceutics14030531 - 27 Feb 2022

Cited by 6 | Viewed by 1872

Abstract

The drugs concept has changed during the last few decades, meaning the acceptance of not only low molecular weight entities but also macromolecules as bioagent constituents of pharmaceutics. This has opened a new era for a different class of molecules, namely proteins in general and enzymes in particular. The use of enzymes as therapeutics has posed new challenges in terms of delivery and the need for appropriate carrier systems. In this review, we will focus on enzymes with therapeutic properties and their applications, listing some that reached the pharmaceutical market. Problems associated with their clinical use and nanotechnological strategies to solve some of their drawbacks (i.e., immunogenic reactions and low circulation time) will be addressed. Drug delivery systems will be discussed, with special attention being paid to liposomes, the most well-studied and suitable nanosystem for enzyme delivery in vivo. Examples of liposomal enzymatic formulations under development will be described and successful pre-clinical results of two enzymes, L-Asparaginase and Superoxide dismutase, following their association with liposomes will be extensively discussed. Full article

(This article belongs to the Special Issue A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines)

► Show Figures

Journal Menu

Journal Browser

Special Issue "A Commemorative Issue in Honor of Professor Gregory Gregoriadis: Liposomes for the Delivery of Drugs and Vaccines"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (6 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI